Tesamorelin Peptide Therapy

Tesamorelin Peptide Therapy is an innovative treatment utilizing a Growth Hormone-Releasing Hormone (GHRH) analog to naturally stimulate the body's pituitary gland. This therapy is designed to reduce visceral adipose tissue, particularly in individuals with conditions leading to central obesity or HIV-associated lipodystrophy. Patients undergo a thorough medical evaluation followed by a consistent self-administration protocol to achieve significant improvements in body composition and overall metabolic health.

Quick answer

Tesamorelin therapy reduces excess abdominal fat and improves body composition by naturally stimulating growth hormone production.

Options

Pick what fits

Benefits

What to expect

  • Significant visceral fat reduction, especially in the abdominal area, while preserving lean muscle mass.
  • Increased skeletal muscle area and density, particularly in truncal and abdominal muscle groups.
  • Reduced cardiovascular disease risk and improved lipid profiles due to visceral fat loss.

Ideal for

Who this helps

Individuals with HIV-associated lipodystrophyPatients with central obesity and elevated cardiovascular riskAdults seeking body composition improvementsIndividuals with documented growth hormone deficiency

How it works

The procedure

01
Tesamorelin, a GHRH analog, binds to GHRH receptors on pituitary somatotroph cells.
02
This binding stimulates the natural pulsatile release of endogenous growth hormone (GH) from the pituitary gland.
03
GH then acts on various tissues, promoting lipolysis in visceral adipose tissue and enhancing protein synthesis in muscle.
04
The sustained elevation of natural GH levels leads to a significant and targeted reduction of visceral fat and improvements in lean muscle mass.

Conditions

Treats

FAQ

Frequently asked

More services

You might also like